-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] Since last week, A-share IPO acceptance companies have ushered in a big explosion, with a total of 275 new acceptance compani.
Among them, there are 13 pharmaceutical manufacturing enterpris.
Specifically, 4 are accepted by the Science and Technology Innovation Board, 4 are accepted by the ChiNext, 2 are accepted by the Shenzhen Main Board, 2 are accepted by the Beijing Stock Exchange, and 1 are accepted by the Shanghai Main Boa.
Among them, Guangzhou Bibet Pharmaceutical .
, L.
(hereinafter referred to as "Bibet") raised a relatively high amount of funds, and plans to raise 005 billion yuan on the Science and Technology Innovation Boa.
According to the prospectus, Bibet is a clinical value-oriented biopharmaceutical enterprise focusing on independent research and development of innovative dru.
The company focuses on major disease areas such as tumors, autoimmune diseases, and metabolic diseas.
The funds to be raised this time are mainly used for new drug research and development projects, Qingyuan research and development center and preparation industrialization base construction projects and supplementary working capit.
It is understood that at present, the core products of Bibbett have not been listed for sale, and the risk warning stated that it has not yet made a profit and is expected to continue to lose mon.
The data shows that from 2019 to 2021, the company's operating income is all other business income, which are 350,500 yuan, 376,900 yuan and 970,300 yuan respectively, and the net profit in the same period is -59375 million yuan, -626 million yuan and -137 million yuan respective.
In addition, the data shows that the company's R&D investment in the past three years is 41592 million yuan, 51175 million yuan and 116 million yuan respectively, and the research and development expenses are relatively high among these 13 compani.
Up to now, the company's R&D pipeline has 6 self-developed innovative drug core products that are in the clinical trial stage or are about to start clinical tria.
In addition to the fact that Bibete on the Science and Technology Innovation Board has not yet made a profit, Suzhou Huyun New Drug Research and Development .
, L.
("Suzhou Huyun") on the Beijing Stock Exchange also has no products on the market and has not generated drug revenue, and it is expected that the products can be list.
, There is still great uncertainty when it will be list.
The data shows that from 2019 to 2021, Suzhou Huyun realized net profits attributable to owners of the parent company of -26477 million yuan, -45348 million yuan, and -53313 million yuan respective.
It is reported that Suzhou Huyun plans to invest a total of 450 million yuan of raised funds this time, which will all be used for innovative drug R&D projects, innovative drug R&D and production base construction projects and supplementary working capit.
According to the prospectus, Suzhou Huyun is an innovation-driven small molecule new drug research and development enterprise based on natural products for drug discovery and developme.
Its research and development pipeline covers cardiovascular and cerebrovascular (such as stroke, heart failure), autoimmunity (such as psoriasis, Disease areas with unmet clinical needs, such as inflammatory bowel diseas.
As of the signing date of this prospectus, the company's research product SPT-07A is undergoing Phase III clinical trials; HY0721 has completed Phase I clinical trials and is preparing for Phase II clinical trials; HY1770 is in Phase I clinical trials; HY1839 has obtained clinical trials Licensed, the company has not yet achieved commercial production and sales of the produ.
From the perspective of R&D expenses, in addition to the high R&D expenses of Bibet (223 million yuan in the three years from 2019 to 2021), the R&D of Guangzhou Green Cross Pharmaceutical .
, L.
and Shanghai Rongsheng Biopharmaceutical .
, L.
The cost is also relatively high, with a total of 161 million yuan and 116 million yuan in the three years from 2019 to 2021, respective.
It is reported that the funds raised by Guangzhou Green Cross Pharmaceutical .
, L.
will be used for the project and the amount of funds to be invested is: the production base construction project (Phase I), the investment amount of the raised funds is about 580 million yuan; the Green Cross drug research and development project, raised The capital investment amounted to 150 million yuan; the working capital was supplemented, and the raised capital investment amounted to about 270 million yu.
It is planned to be listed on the GEM of the Shenzhen Stock Exchange after the issuance of the shar.
Shanghai Rongsheng Biopharmaceutical .
, L.
plans to raise 25 billion yuan this time for vaccine research and development and industrialization projec.
According to the prospectus, Rongsheng Bio’s business mainly includes vaccines and in vitro diagnosti.
In recent years, vaccines are the main busine.
In 2021, more than 82% of Rongsheng Bio's main business revenue will be contributed by vaccine produc.
In addition, on July 5, Hebei Jiheng Pharmaceutical .
, L.
submitted an application draft for an IPO prospect.
According to this, the company plans to sprint for IPO on the main board of Shenzhen Stock Exchan.
The total investment of the company's proposed investment projects this time is 265 billion yuan, and it plans to invest 2 billion yuan in fundraisi.
Comprehensive preparation project, construction project of characteristic raw material drug production line, construction project of R&D center and supplementary working capit.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Among them, there are 13 pharmaceutical manufacturing enterpris.
Specifically, 4 are accepted by the Science and Technology Innovation Board, 4 are accepted by the ChiNext, 2 are accepted by the Shenzhen Main Board, 2 are accepted by the Beijing Stock Exchange, and 1 are accepted by the Shanghai Main Boa.
Among them, Guangzhou Bibet Pharmaceutical .
, L.
(hereinafter referred to as "Bibet") raised a relatively high amount of funds, and plans to raise 005 billion yuan on the Science and Technology Innovation Boa.
According to the prospectus, Bibet is a clinical value-oriented biopharmaceutical enterprise focusing on independent research and development of innovative dru.
The company focuses on major disease areas such as tumors, autoimmune diseases, and metabolic diseas.
The funds to be raised this time are mainly used for new drug research and development projects, Qingyuan research and development center and preparation industrialization base construction projects and supplementary working capit.
It is understood that at present, the core products of Bibbett have not been listed for sale, and the risk warning stated that it has not yet made a profit and is expected to continue to lose mon.
The data shows that from 2019 to 2021, the company's operating income is all other business income, which are 350,500 yuan, 376,900 yuan and 970,300 yuan respectively, and the net profit in the same period is -59375 million yuan, -626 million yuan and -137 million yuan respective.
In addition, the data shows that the company's R&D investment in the past three years is 41592 million yuan, 51175 million yuan and 116 million yuan respectively, and the research and development expenses are relatively high among these 13 compani.
Up to now, the company's R&D pipeline has 6 self-developed innovative drug core products that are in the clinical trial stage or are about to start clinical tria.
In addition to the fact that Bibete on the Science and Technology Innovation Board has not yet made a profit, Suzhou Huyun New Drug Research and Development .
, L.
("Suzhou Huyun") on the Beijing Stock Exchange also has no products on the market and has not generated drug revenue, and it is expected that the products can be list.
, There is still great uncertainty when it will be list.
The data shows that from 2019 to 2021, Suzhou Huyun realized net profits attributable to owners of the parent company of -26477 million yuan, -45348 million yuan, and -53313 million yuan respective.
It is reported that Suzhou Huyun plans to invest a total of 450 million yuan of raised funds this time, which will all be used for innovative drug R&D projects, innovative drug R&D and production base construction projects and supplementary working capit.
According to the prospectus, Suzhou Huyun is an innovation-driven small molecule new drug research and development enterprise based on natural products for drug discovery and developme.
Its research and development pipeline covers cardiovascular and cerebrovascular (such as stroke, heart failure), autoimmunity (such as psoriasis, Disease areas with unmet clinical needs, such as inflammatory bowel diseas.
As of the signing date of this prospectus, the company's research product SPT-07A is undergoing Phase III clinical trials; HY0721 has completed Phase I clinical trials and is preparing for Phase II clinical trials; HY1770 is in Phase I clinical trials; HY1839 has obtained clinical trials Licensed, the company has not yet achieved commercial production and sales of the produ.
From the perspective of R&D expenses, in addition to the high R&D expenses of Bibet (223 million yuan in the three years from 2019 to 2021), the R&D of Guangzhou Green Cross Pharmaceutical .
, L.
and Shanghai Rongsheng Biopharmaceutical .
, L.
The cost is also relatively high, with a total of 161 million yuan and 116 million yuan in the three years from 2019 to 2021, respective.
It is reported that the funds raised by Guangzhou Green Cross Pharmaceutical .
, L.
will be used for the project and the amount of funds to be invested is: the production base construction project (Phase I), the investment amount of the raised funds is about 580 million yuan; the Green Cross drug research and development project, raised The capital investment amounted to 150 million yuan; the working capital was supplemented, and the raised capital investment amounted to about 270 million yu.
It is planned to be listed on the GEM of the Shenzhen Stock Exchange after the issuance of the shar.
Shanghai Rongsheng Biopharmaceutical .
, L.
plans to raise 25 billion yuan this time for vaccine research and development and industrialization projec.
According to the prospectus, Rongsheng Bio’s business mainly includes vaccines and in vitro diagnosti.
In recent years, vaccines are the main busine.
In 2021, more than 82% of Rongsheng Bio's main business revenue will be contributed by vaccine produc.
In addition, on July 5, Hebei Jiheng Pharmaceutical .
, L.
submitted an application draft for an IPO prospect.
According to this, the company plans to sprint for IPO on the main board of Shenzhen Stock Exchan.
The total investment of the company's proposed investment projects this time is 265 billion yuan, and it plans to invest 2 billion yuan in fundraisi.
Comprehensive preparation project, construction project of characteristic raw material drug production line, construction project of R&D center and supplementary working capit.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
